Keyword Analysis & Research: guardant health investor relations

guardanthealth.com

https://investors.guardanthealth.com/home/default.aspx

WEBInvestor Relations. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Liquid biopsy is at the core of our mission to conquer cancer with data.

DA: 34 PA: 52 MOZ Rank: 36

guardanthealth.com

https://ir.guardanthealth.com/

WEBGuardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data. investor relations

investor relations

DA: 20 PA: 39 MOZ Rank: 9

guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-2023-Outlook/

WEBFeb 23, 2023 · Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021. Reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers in the fourth quarter of 2022, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021.

DA: 1 PA: 76 MOZ Rank: 53

guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Reports-Third-Quarter-2022-Financial-Results/default.aspx

WEBNov 3, 2022 · Guardant Health Reports Third Quarter 2022 Financial Results. November 3, 2022. Q3 clinical and biopharma volumes up 42% and 40% year over year. PALO ALTO, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, …

DA: 7 PA: 49 MOZ Rank: 83

guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Reports-Fourth-Quarter-2021-Financial-Results-and-Provides-2022-Outlook/default.aspx

WEBFebruary 23, 2022. Q4 clinical and biopharma volumes up 48% and 36% year over year. REDWOOD CITY, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial ...

DA: 15 PA: 79 MOZ Rank: 64

guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Reports-Third-Quarter-2021-Financial-Results/default.aspx

WEBNov 4, 2021 · Cash, cash equivalents and marketable securities were $1.7 billion as of September 30, 2021. 2021 Guidance. Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Webcast Information.

DA: 15 PA: 77 MOZ Rank: 96

guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-to-Report-Second-Quarter-2022-Financial-Results-on-August-4-2022/default.aspx

WEBJul 13, 2022 · Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

DA: 35 PA: 24 MOZ Rank: 87

guardanthealth.com

https://guardanthealth.com/2022/11/03/guardant-health-reports-third-quarter-2022-financial-results/

WEBNov 3, 2022 · Guardant Reveal for Early-Stage Cancer; Guardant 360 Portfolio for Advanced Cancer; Biopharma Solutions

DA: 17 PA: 77 MOZ Rank: 54

businesswire.com

https://www.businesswire.com/news/home/20240108590229/en/Guardant-Health-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-Results/

WEBJan 8, 2024 · Fourth quarter 2023 preliminary unaudited financial results. For the three-month period ended December 31, 2023, as compared to the same period of 2022: Revenue of between $153 million and $154 ...

DA: 7 PA: 7 MOZ Rank: 50

businesswire.com

https://www.businesswire.com/news/home/20230509005527/en/Guardant-Health-Reports-First-Quarter-2023-Financial-Results/

WEBMay 9, 2023 · Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022. Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical ...

DA: 78 PA: 48 MOZ Rank: 27